San Francisco Bay Area biotech stories.
Tuesday, July 31, 2012
FibroGen wins orphan designation for IPF drug
mid-stage experimental treatment for the lung-scarring disease idiopathic pulmonary fibrosis was granted orphan drug designation
. The drug, FG-3019, is a human monoclonal antibody designed to inhibit connective tissue growth factor, a protein that plays an important role in the build up of excessive fibrous tissue in diseases like IPF.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)